cyrilzakka/clinical-trials huggingface dataset:
Recovery of TIVA vs Inhalation in Pediatric Anesthesia

Compare recovery profile from TIVA and that of total inhalational anesthesia in ambulatory pediatric tonsillectomy and which strategy is more safe and less cost and more smooth in pediatric anesthesia.

Complications in pediatric anesthesia can happen even in our modern hospitals with the most advanced equipment and skilled anesthesiologists.

Typical complications in pediatric anesthesia are respiratory problems , medication errors , difficulties with intravenous puncture , and pulmonal aspiration. In postoperative setting , nausea and vomiting , pain , emergence delirium can be mentioned as typical complications.

The choice of anesthetic agent and techniques can influence the occurrence of these complications and thus delay in discharge.

Eligibility Criteria:
Inclusion Criteria:

* child between 4 to 10 years
* without co morbidity
* ASA score 1
* mallampati score 1 and 2

Exclusion Criteria:

* child below 4 years and above 10 years
* child with co morbidity
* ASA score above 1
* mallampati score 3 and 4
Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients

Although arginine vasopressin has been used as an additional drug in refractory shock in worldwide clinical practice, there are no prospective studies using it as a first choice therapy in patients with cancer and septic shock.

The aim of this study is assess if the use of arginine vasopressin would be more effective on treatment of septic shock in cancer patients than norepinephrine, decreasing the composite end point of mortality and organ failure in 28 days.


Eligibility Criteria:
Inclusion Criteria:

* Solid neoplasm needing ICU
* Septic Shock according standard criteria

Exclusion Criteria:

* Younger than 18 years;
* Pregnancy;
* Raynaud's phenomenon, systemic sclerosis or vasospastic diathesis;
* Severe hyponatremia (Na\<130mEq/L);
* Acute mesenteric ischemia;
* Acute myocardial infarction;
* Cardiogenic shock;
* Current use of vasopressor before randomization
* Expected ICU stay less than 24 hours
* Enrolled in another study;
* Refusal to consent.
Application of Three- Dimensional Visualization Combined With ICG Molecular Fluorescence Imaging in Hepatolithiasis

This study adopted a retrospective study method to explore the clinical application value of 3D visualization combined with ICG molecular fluorescence imaging technology in hepatolithiasis, and further analyze whether 3D visualization combined with ICG molecular fluorescence imaging technology can improve the prognosis of hepatolithiasis by comparing with conventional surgery.

Hepatolithiasis is a complex and intractable benign disease, often called "benign disease with poor prognosis". Clinical practice has proved that the diagnosis and treatment platform for hepatolithiasis built by modern digital image technologies such as 3D visualization and Indocine green fluorescence image navigation technology plays a vital leading role in accurate preoperative assessment, location of the lesion, formulation of the best surgical plan, and intraoperative navigation to avoid collateral damage. The clinical practice has proved that the diagnosis and treatment platform for hepatolithiasis built by modern digital image technologies such as 3D visualization and ICG fluorescence image navigation plays a vital leading role in accurate preoperative assessment, location of the lesion, formulation of the best surgical plan, and intraoperative navigation to avoid collateral damage.Therefore, we want to conduct a retrospective cohort study to explore the application value of 3D visualization combined with ICG fluorescence technology in hepatolithiasis, in order to further improve the curative effect of hepatolithiasis.

Eligibility Criteria:
Inclusion Criteria:

* Patients aged ≥18 years, of any gender; The diagnosis was hepatolithiasis；Surgical treatment has been performed.

Exclusion Criteria:

* Patients with severe cardiac, pulmonary, cerebral, renal dysfunction or other clinical contraindications who are unable to tolerate surgical treatment; Patients with malignant transformation; Lack of clinical data.
Study to Assess Effect and Safety of High Dose of Biotin (Qizenday®) in Progressive Multiple Sclerosis

The purpose of this observational study is to collect efficacy and safety data in real life condition within the first year of treatment in patients with progressive multiple receiving a daily dose of biotine of 300 mg.


Eligibility Criteria:
Inclusion Criteria:

* Progressive multiple sclerosis patients with an EDSS score ≤ 7 who have been prescribed high dose of biotin (temporary use administration) at Nantes university hospital (France)

Exclusion Criteria:

* Patient with remittent recurrent multiple sclerosis
* Pregnant women or women contemplating pregnancy
Quantification of Parkinson's Disease Patients As a Biomarker for Classification, Prediction and Response to Treatment

This is a three-armed open investigational study that aims to differentiate, quantify, and categorize abnormal eye movements and upper limbs movements in patients with Parkinson's disease. The study is using investigational non-invasive devices for that reason including ANLIVA® Hand Movement and ANLIVA® Eye Movement.

To evaluate performance of mathematical models developed to quantify and classify symptoms and disease state using sensor data from smart phone and eye tracking cameras in subjects with Parkinson's disease.

A clinical investigator will be capturing data from the clinical encounter completed by default the same day in addition to other clinical questionnaires subjects will be filling themselves. A percentage of subjects will be asked prior to their arrival to be part of a subset study called OFF/ON study, where they will be asked not to take their IPD oral home medications prior to arrival. Both study procedure elements will be performed at the beginning of the evaluation and 60 minutes after taking their medication. There is also a longitudinal study part, where a percentage of the subjects will be asked to visit the clinic with 6 months interval, up to 4 times, including the first visit. There will be a percentage of approached subjects that belong to the category of Essential Tremor (ET) and Healthy control (HC) used for comparison purposes. ET and HC subjects will undergo the same recruitment and testing process.

Eligibility Criteria:
Inclusion Criteria:

For inclusion in the investigation, the subjects must fulfil all the below criteria prior to enrolment:

1. Subjects already diagnosed with Idiopathic Parkinson's Disease (IPD)
2. or subjects already diagnosed with Essential tremor (ET)
3. or subjects who are healthy controls (HC) and are not diagnosed with IPD or ET
4. Able to understand and sign the informed consent form.

Exclusion Criteria:

Subjects that meet any of the below criteria will be excluded:

1. Not able to sign the informed consent form
2. Below 18 years of age
3. Diagnosed with movement disorder other than IPD or ET that might interfere with hand movements or eye movements (tics, myoclonus, chorea, dystonia, etc)
4. Has parkinsonism not due to IPD (drug induced, functional, vascular, etc)
5. Visual or physical limitations that prevent the subject from performing the baseline eye study requirements
6. Being involved in the planning and conduct of the clinical investigation (applies to all sponsor management staff, investigational staff and third-party vendors as applicable)
Effect of High-dose Pitavastatin on Glucose Control in Patients With Metabolic Syndrome

This purpose of this study is to evaluate effect of high-dose Pitavastatin on glucose control in patients with metabolic syndrome.


Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed as metabolic syndrome according to National cholesterol Education Program criteria
* Patients with hypercholesterolemia who required to start statin therapy

Exclusion Criteria:

* overt diabetes
* acute coronary syndrome within 2 months
* acute cerebrovascular event within 2 months
* recent treatment of statin within 1month
* recent diagnosed neoplasm
* recent diagnosed liver disease
* chronic kidney disease
* patients with myopathy
* pregnant women, nursing mothers, women with possibility of pregnant
* patients being adminstered cyclosporine
* patients with genetic disease such as galactose intolerance, lactose intolerance, glucose-galactose malabsorption
* patients with treatment cyclosporin
Physical Activity Pathway for Patients With Osteoarthritis in Primary Care (OA-PCP) (R33)

The purpose of this study is to test an osteoarthritis (OA) primary care Physical activity Care Pathway (OA-PCP), a scalable intervention that includes: 1) a practical process for physical inactivity screening in primary care, 2) a brief, tailored physical activity (PA) counseling intervention via telephone, 3) connection of patients with community programs and other resources to support PA, and 4) follow-up with patients to deliver additional appropriate counseling and referrals to PA resources. This program will be compared to another program that provides education on a variety of topics important to understanding osteoarthritis (OA) and its care.

This study will be a randomized pilot trial of the refined OA-PCP among n=240 patients age ≥65 with hip and/or knee OA recruited from primary care clinics. Participants will be assigned equally to either the OA-PCP or an attention control group. Participants will complete assessments at baseline, and 6-month and 12-month follow-up. Primary endpoint of the trial will be objectively assessed PA, measured via accelerometer and secondary endpoint will be self-reported pain and function.

Eligibility Criteria:
Inclusion Criteria:

* Age 65 or older
* One other chronic health condition that qualified under Chronic Care Management (CCM) guidelines, including: diabetes, depression, hypertension, hyperlipidemia, heart failure, atrial fibrillation, ischemic heart disease, stroke/transient ischemic attack (TIA), peripheral vascular disease, Chronic obstructive pulmonary disease (COPD), bronchiectasis, asthma, rheumatoid arthritis, osteoarthritis, HIV/AIDS, chronic kidney disease, hepatitis (chronic \& viral B \& C) and osteoporosis
* Current Joint Symptoms
* Self-reported physical activity \<150 minutes per week
* Willing to make a change in PA over the next 3 months

Exclusion Criteria:

* Pain in chest when performing physical activity
* Pain in chest when not performing physical activity
* Loss of balance because of dizziness or loss of consciousness
* Recommendation from doctor to only perform physical activity under medical supervision
* No documented diagnosis of knee or hip OA
* Dementia or other memory loss condition
* Active diagnosis of psychosis
* Active Substance abuse disorder
* Total knee or hip replacement surgery, meniscus tear, ligament tear, or other significant lower extremity injury or surgery in the last 6 months
* Severe hearing or visual impairment
* Serious/terminal illness as indicated by referral to hospice or palliative care
* Unstable angina
* Hospitalization for cardiovascular event in last 6 months
* History of ventricular tachycardia
* Unstable chronic obstructive pulmonary disease (2 hospitalizations within the previous 6 months and/or on oxygen)
* Stroke with moderate to severe aphasia
* Recent history (last 6 months) of three or more falls
Effects of Macronutrients on Hepatic Lipids, Plasma Triglycerides, and Insulin Sensitivity

The purpose of this study is to assess how the macronutrient composition of the diet effects

* lipid and glucose metabolism
* intrahepatic lipids
* insulin sensitivity

in healthy lean subjects and in subjects with a high metabolic risk (ie overweight and offsprings of patients with type 2 diabetes mellitus).

The study is aimed at assessing the effects of changes in total energy, sugars, lipids, and protein intake on intrahepatic lipids, plasma lipids, and hepatic and whole body insulin resistance in

* lean men and women with no family history of diabetes
* overweight men and women
* lean men with a family history of type 2 diabetes

Subjects are studied after a 6-day period of

* isocaloric diet with 100% calorie requirement, of which 55% carbohydrate, 15% protein, and 30% fat)
* the same isocaloric diet supplemented with 3g/kg body weight/day fructose
* hypercaloric high fat diet with 130% energy requirement, of which 55% carbohydrate, 15% protein, 60% fat
* hypercaloric high fat+protein diet with 145% energy requirement, of which 55% carbohydrate, 30% protein, 60% fat

Measurements performed after 6 days on each diet include

* intrahepatic and intramyocellular lipids (1H-MRS)
* hepatic and whole body insulin sensitivity (hyperinsulinemic-euglycemic clamp)
* body weight
* plasma concentrations of hormones and substrates
* gene expression profile in skeletal muscle (vastus lateralis) and adipose tissue (subcutaneous abdominal)

Eligibility Criteria:
Inclusion Criteria:

* Males and females
* Age 18-40
* Informed consent obtained
* Subgroup with overweight (body mass index \[BMI\] \> 25)
* Subgroup with family history of type 2 diabetes mellitus

Exclusion Criteria:

* Smokers
* Alcohol intake \> 30g/day
* Drug abuse
* Diabetes mellitus
* Any concurrent medication
* Having a pacemaker
* History of orthopedic surgery
* History of metal foreign bodies
NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer

The purpose of this study is to evaluate the safety and feasibility of the NanoKnife Low Energy Direct Current (LEDC) System when used to treat unresectable pancreatic adenocarcinoma. Safety will be reviewed by means of analysis of adverse events, including serious adverse events, laboratory data, physician exam findings, and vital signs.


Eligibility Criteria:
Inclusion Criteria:

1. male or female
2. \>/= 18 years of age
3. meets criteria for locally advanced unresectable pancreatic adenocarcinoma, as radiographically proven pancreatic cancer as determined by a surgical oncologist via pancreatic CT or who were initially thought to be resectable; however at the time of surgery were upstaged to unresectability, via direct visualization
4. tumor size must be \< 4 cm and must be measurable
5. must have an INR \<1.5
6. must be unresponsive to chemotherapy as demonstrated with either CT or MR imaging and not have taken any chemotherapy agents within 14 days of treatment with the NanoKnife LEDC System
7. are willing and able to comply with the protocol requirements
8. are able to comprehend and willing to sign an Informed Consent Form (ICF)

Exclusion Criteria:

1. a baseline creatinine reported as \> 2.0 mg/dL
2. have any reported baseline lab values with a grade 3 or 4 toxicity as defined by the CTCAE Version 3.0
3. inability to stop antiplatelet and Coumadin therapy for 7 days prior to and 7 days post treatment with the NanoKnife System
4. known history of contrast allergy that cannot be medically managed
5. known hypersensitivity to the metal in the electrodes (stainless steel 304L) that cannot be medically managed
6. unable to be treated with a muscle blockade agent (e.g. pancuronium bromide, atracurium, cisatracurium, etc)
7. women who are pregnant or currently breast feeding
8. women of childbearing potential who are not utilizing an acceptable method of contraception
9. have taken an investigational agent within 30 days of visit 1
10. have implanted cardiac pacemakers or defibrillators
11. have implanted electronic devices or implants with metal parts in the immediate vicinity of a lesion
12. have a history of epilepsy or cardiac arrhythmia (atrial or ventricular fibrillation)
13. have a recent history of myocardial infarction (within the past 2 months)
14. have Q-T intervals greater than 550 ms unless treated with an Accysync Model 72 synchronization system controlling the NanoKnife system's output pulses.
The Hypoalgesic Effects of Low Load Blood Flow Restriction Training (BFRT)

A randomized controlled trial comparing the immediate effects of upper limb low-load blood flow restriction training (BFRT) with high load sham-BFRT on hypoalgesia and perceptual response in healthy adults

Healthy individuals will be randomized to one of two groups. A target of 40 patients for enrollment has been set for 80% power, p\<0.05 (Effect size= 1). A single Intervention will be used (40 minutes).

Intervention Group: A single exercise of elbow flexion with Blood Flow Restriction (30-15-15-15 reps) using 30% of 1 Repetition Maximum.

Control Group: A single exercise of elbow flexion with sham Blood Flow Restriction (4x10 reps) using 65% of 1 Repetition Maximum.

Primary outcome: pressure pain thresholds on quadriceps, biceps, lateral epicondyle and upper trapezius (bilateral).

Secondary outcomes: difference in perceptual response (exertion), change in blood pressure

Eligibility Criteria:
Inclusion Criteria:

* BMI\< 30
* able to perform full elbow flexion and extension

Exclusion Criteria:

* shoulder tendinopathy,
* cervical radiculopathy,
* rheumatoid arthritis,
* neurological deficit,
* serious cardiovascular diseases,
* venous deficiency,
* history of heart surgery,
* cancer history,
* breast surgery,
* orthopaedic surgeries during the last 6 months,
* thrombosis,
* diabetes,
* body mass Index ≥ 30,
* Crohn syndrome,
* family or personal history of pulmonary embolism
Predictive Value of NT-proBNP on MACEs After Acute Coronary Syndrome

The role of N-terminal pro-B-type natriuretic peptide (NT-proBNP) as a cardiac biomarker in predicting short-term major adverse cardiovascular events (MACEs) in patients with Acute coronary syndrome (ACS) has been insufficiently reported and remains poorly understood. Additionally, the relationship between NT-proBNP levels and specific ACS subtypes has not been thoroughly examined. Therefore, our study investigated the predictive value of high-sensitivity cardiac troponin (hs-cTn) and NT-proBNP levels on admission for 6-month MACEs in patients who presented to the emergency department (ED) with ACS and subsequently underwent percutaneous coronary intervention (PCI). Furthermore, we sought to evaluate the association between MACEs and specific ACS subtypes.

In patients diagnosed with Acute coronary syndrome (ACS) based on anamnesis, clinical findings, electrocardiogram (ECG), and/or serum high-sensitivity cardiac troponin (hs-cTn) level in the emergency department (ED), blood samples for serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) value was additionally taken during transfer to the coronary intensive care unit, and left ventricular ejection fraction (LVEF) was calculated by echocardiography before percutaneous coronary intervention (PCI). In addition, demographics (age, sex, and smoking status), comorbidities (hypertension, diabetes mellitus \[DM\] and/or coronary artery disease \[CAD\]), initial complaints and diagnoses, vital signs (systolic blood pressure \[SBP\], heart rate \[HR\], and peripheral capillary oxygen saturation \[SpO2\]), laboratory parameters (serum creatinine, C-reactive protein, and hs-cTn), and ACS subtypes (ST-elevation Myocardial infarction \[STEMI\], non-ST-elevation Myocardial infarction \[NSTEMI\], or unstable angina pectoris \[USAP\]) were obtained during admission. GRACE risk score was calculated for each patient on admission using eight variables, including age, SBP, HR, and serum creatinine. At the end of the 6-month follow-up period, LVEF of surviving patients was assessed by control echocardiography. The short-term MACEs (e.g., nonfatal ischemic stroke, nonfatal myocardial infarction, cardiovascular mortality, or ED admission due to heart failure) were recorded.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients (≥18 years old) who were admitted to the emergency department with Acute coronary syndrome and underwent percutaneous coronary intervention between September 2023 and February 2024.

Exclusion Criteria:

* patients younger than 18 years
* patients had no vascular lesions detected on percutaneous coronary intervention,
* patients had infective or structural cardiac pathologies (myocarditis, pericarditis, hypertrophic or dilated cardiomyopathies)
* patients had chronic heart failure with LVEF \<40%, class 3 and 4 in the Killip classification
* patients had a diagnosis of malignancy, chronic renal failure, chronic liver failure, and a history of multiple trauma or surgery within the last month
GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma

Objective of study: To evaluate the safety and efficacy of infusional gemcitabine prior to HDM (high-dose melphalan) as HDCT (High Dose Chemotherapy) followed by autologous stem cell transplantation in patients with relapsed/refractory lymphoma.

High-dose chemotherapy with autologous stem cell transplantation is the current standard of care for patients with chemosensitive relapsed Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma, and is an established effective therapy for patients with relapsed follicular lymphoma. Disease relapse remains a major problem, occurring in 50% of these patients, particularly in patients with primary refractory disease or other high-risk features. The addition of gemcitabine to single-agent melphalan as a high-dose conditioning regimen presents a promising combination that may lead to improvements in EFS (Event free survival). If this trial gives encouraging results, it may lead to a phase III trial evaluating this treatment strategy.

Drug exposure would be AUC (area under curve) and clinical factors would be things like obesity, renal function, disease characteristics.

We would be looking at the safety outcomes - i.e. adverse events as a measure of safety and tolerability. The adverse events would be non-hematological toxicities (any) and whether or not it is related to AUC. AUC in relationship to PFS (progression free survival) is also important (we want to know if we need to adjust dose to improve PFS).

Eligibility Criteria:
Inclusion Criteria:

1. Ability to provide written informed consent
2. Age over 18 years
3. Relapsed/refractory lymphoma after at least 1 prior chemotherapy treatment:

   1. Hodgkin's lymphoma
   2. Aggressive non-Hodgkin's lymphoma
   3. Follicular lymphoma
4. Chemosensitive disease at time of transplantation (i.e. partial response or better to salvage chemotherapy)
5. ECOG (Eastern Cooperative Oncology Group) performance 0-2
6. Adequate organ function:

   1. Cardiac: LVEF (left ventricular ejection fraction)\>40%
   2. Pulmonary: FEV1 (forced expiratory volume at one second) and DLCO (diffusing capacity of lung for carbon monoxide)\>60% predicted
   3. Renal: creatinine \<150 µmol/L unless caused by ureteric obstruction from lymphoma
   4. Liver: No evidence of cirrhosis. ALT (Alanine Aminotransferase) and bilirubin \<2x upper limit of normal unless caused by biliary tract obstruction from lymphoma

Exclusion Criteria:

1. Clinically significant active infection
2. Active secondary central nervous system disease
3. Other serious co-morbid illness that would compromise study participation.
4. Pregnant or lactating females
5. Prior HDCT/ASCT